Project Grant R21AI184484
Award Date
8/1/24
Completion Date
6/30/26
Dollars Obligated
$467K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This $499,151 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel diagnostic test for syphilis infection. The project aims to create an immuno-PCR diagnostic platform that can detect unique peptidoglycan fragments shed by the syphilis-causing bacterium, Treponema pallidum, in order to provide early-stage diagnosis of the disease. This...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care molecular test to detect Treponema pallidum antibiotic resistance. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is for the development of a direct diagnostic test for infectious and congenital syphilis. The $260,760 award to the University of Victoria aims to create a test that: (1) exhibits high sensitivity and specificity at all disease stages; (2) can differentiate active versus past infections; (3) can differentiate syphilis from yaws;...
This federal Project Grant award, valued at $771,690.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate syphilis pathogenesis through genetic engineering of the syphilis-causing bacteria Treponema pallidum. The award aims to leverage new capabilities to genetically manipulate T. pallidum in order to better understand the role of antigenic variation in the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $264,750 to the University of Washington to optimize methods for recovering the Treponema pallidum genome from diverse clinical specimens. The project aims to develop a tiling amplicon sequencing approach to improve the analytical sensitivity and scale of T. pallidum genome recovery, which is challenging due to the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $163,698 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Magic Lifescience, Inc. in Mountain View, CA to develop a novel point-of-care molecular diagnostic assay for syphilis as part of a multiplexed genital ulcer disease (GUD) test panel. The key objectives are to: 1) develop a PCR-based, multiplexed molecular assay for Treponema pallidum (syphilis) and other GUD pathogens using giant...
The University of Texas at Austin received a $212,357 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of this project is to develop a rapid, sensitive, and specific point-of-care diagnostic test for detecting congenital syphilis in newborns, as well as an improved maternal syphilis diagnostic using vaginal self-swabs. The key products to be delivered include: A...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to optimize molecular polymerase chain reaction (PCR) testing for the detection of congenital syphilis. The $246,000 award, effective August 20, 2024 through July 31, 2026, will fund research to determine the optimal diagnostic specimen(s) and sampling strategy for PCR-based detection of Treponema pallidum in...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a novel suite of local-level syphilis epidemiologic and economic models (LSEEM) across 40 U.S. cities with the highest syphilis diagnosis rates. The $1,550,917 award, spanning from July 2024 to May 2029, aims to assess the potential impact of scaling up existing syphilis control...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $135,258 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Virginia Polytechnic Institute & State University (Virginia Tech) on September 13, 2024. The grant will fund research to determine the biochemical features of Treponema pallidum peptidoglycan and the identity of released muropeptides, as well as elucidate the role of released peptidoglycan in the pathogenesis of...